Exelixis.
American biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 84
What's happening
Earlier this month
-
Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.Some support4 reports
-
GRAIL and Exelixis, both healthcare companies, are competing for investment.Some support1 report
-
The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Some support1 report
-
Exelixis stock trades on the Nasdaq electronic stock exchange.Some support1 report
-
TD Cowen raised its price target on Exelixis shares on August 30, 2026.Some support1 report
One to three months ago
-
NET revenue ramp slows, Exelixis drug is under FDA review, and Ipsen receives royalties from cabozantinib sales.Some support3 reports
-
Truist Financial adjusted its rating and TD Cowen lifted its target price for Exelixis stock.Some support1 report
-
Exelixis insiders sold shares and filed the required disclosure with the SEC on July 1, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Exelixis filed required disclosures regarding share holdings with the Securities and Exchange Commission.Some support1 report
-
Zacks Analyst Blog recommended Exelixis and Sprouts Farmers Market, while gold prices drove safe-haven demand for Royal Gold.Speculative1 report
-
The new event lists the headquarters and operational areas for Exelixis, Kinross Gold, and Lyft.Speculative2 reports
-
Cabometyx drove strong financial results for Exelixis in July 2025.Some support2 reports
-
Zacks Investment Research provided stock analysis and rankings for Exelixis on July 4, 2025. The company is based in Alameda, CA.Speculative3 reports
-
A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.Some support1 report1 development inside
-
Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.Speculative1 report
-
Exelixis operates within the biomedical and genetics industry.Some support6 reports
-
Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.Some support2 reports1 development inside
-
Exelixis and argenex SE are identified as stocks within the medical and biomedical investment sector.Some support1 report
-
Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.Some support1 report
-
Exelixis stock performance on July 23, 2025, contrasted with the movement of the S&P 500.Some support2 reports
-
Exelixis captured market share in NET and Morrissey was named CEO on July 29, 2025.Some support1 report
-
Exelixis received a rating upgrade following an upward trend in earnings estimates, which institutional investors use for valuation.Some support2 reports
-
Celestica and Exelixis were reported as highly ranked stocks following their Q2 earnings reports in July 2025.Some support1 report
-
The National Cancer Institute (NCI) has been associated with Exelixis since July 30, 2025.Some support1 report
-
Exelixis reported on August 4, 2025, that Europe contributed 6.5% of its total revenue, alongside 1.1% from Japan.Some support1 report
-
Exelixis's CABOMETYX received FDA approval for neuroendocrine tumors (NET) on September 5, 2025.Some support3 reports
-
Exelixis conducted the STELLAR-305 trial, investigating zanzalintinib and pembrolizumab, while Robert Burns maintained a Buy rating.Some support1 report
-
Zacks Investment Research provided stock analysis and recommendations for Exelixis on August 30, 2025.Some support1 report
-
Dana T. Aftab was appointed Executive Vice President, R&D at Exelixis on August 30, 2025.Some support1 report
-
Exelixis, a company, is headquartered in Alameda, California.Well supported5 reports
No events began in the chosen period. Widen it, or reset.
Around Exelixis this week
News at the entities that move Exelixis most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Exelixis
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Exelixis
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Exelixis
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Exelixis
-
Hoffmann-La Roche OperationalNvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.Moves Exelixis
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Exelixis
Connections
The 22 strongest of 84, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Andrew Brown Structural
Andrew Brown is a founding partner of Exelixis, establishing a foundational and ongoing professional link.
-
FDA Structural
FDA acts as the primary regulatory body, granting market approvals and overseeing product development for Exelixis.
-
Ipsen Operational
Ipsen and Exelixis maintain an operational partnership involving supply and collaboration revenue sharing.
-
Securities and Exchange Commission Structural
Exelixis is subject to mandatory regulatory oversight by the Securities and Exchange Commission regarding its share holdings and market operations.
-
Hoffmann-La Roche Operational
Exelixis utilizes Roche's Tecentriq product as part of a combined therapeutic approach.
-
Morgan Stanley Operational
Morgan Stanley actively influences Exelixis through research ratings and financial investments, while Exelixis participates in MS events.
-
Andrew Peters Structural
Andrew Peters holds the functional role of Senior Vice President of Strategy for Exelixis.
-
Ipsen Structural
Ipsen receives royalties from cabozantinib sales, indicating a structural financial dependency on Exelixis's product.
Show all 22 connections
-
SEC Structural
Exelixis operates under regulatory requirements and filing mandates enforced by the SEC.
-
Food and Drug Administration Structural
The FDA regulates Exelixis, impacting the approval and market status of its cancer treatments.
-
TD Cowen Mentioned together
TD Cowen issued an analyst report that raised its price target for Exelixis stock.
-
NET Operational
Exelixis is actively competing with NET by capturing market share and treating the same neuroendocrine tumors.
-
Merck Operational
Exelixis and Merck actively compete in the renal cell carcinoma market and engage in collaborative research studies.
-
Michael Morrissey Structural
Michael Morrissey serves as the CEO of Exelixis, leading the company through business challenges.
-
GRAIL Operational
Both companies are healthcare entities that compete for investment in the market.
-
David Schwartz Operational
A is under investigation for securities law violations related to Exelixis' market operations and investor losses.
-
MarketBeat Mentioned together
MarketBeat aggregates consensus rating data specifically for Exelixis.
-
Truist Financial Mentioned together
Truist Financial provides stock ratings and financial analysis on Exelixis.
-
Wells Mentioned together
Exelixis participated in a biotech session hosted by Wells.
-
Alameda Shared context
A is headquartered in Alameda, California, providing the shared geographical context for the relationship with B.
-
Nasdaq Shared context
Exelixis is listed and trades on the Nasdaq electronic stock exchange.
-
Andy Hsieh Mentioned together
A single analyst prediction noted an unlikely outright rejection related to the entities.
History
Events by the month they beganSeptember 2026
3 eventsAugust 2026
3 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
22 events- Exelixis filed required disclosures regarding share holdings with the Securities and Exchange Commission.
- Zacks Analyst Blog recommended Exelixis and Sprouts Farmers Market, while gold prices drove safe-haven demand for Royal Gold.
- The new event lists the headquarters and operational areas for Exelixis, Kinross Gold, and Lyft.
- Cabometyx drove strong financial results for Exelixis in July 2025.
- Zacks Investment Research provided stock analysis and rankings for Exelixis on July 4, 2025. The company is based in Alameda, CA.
- A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
- Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.
- Exelixis operates within the biomedical and genetics industry.
- Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.
- Exelixis and argenex SE are identified as stocks within the medical and biomedical investment sector.
- Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.
- Exelixis stock performance on July 23, 2025, contrasted with the movement of the S&P 500.
- Exelixis captured market share in NET and Morrissey was named CEO on July 29, 2025.
- Exelixis received a rating upgrade following an upward trend in earnings estimates, which institutional investors use for valuation.
- Celestica and Exelixis were reported as highly ranked stocks following their Q2 earnings reports in July 2025.
- The National Cancer Institute (NCI) has been associated with Exelixis since July 30, 2025.
- Exelixis reported on August 4, 2025, that Europe contributed 6.5% of its total revenue, alongside 1.1% from Japan.
- Exelixis's CABOMETYX received FDA approval for neuroendocrine tumors (NET) on September 5, 2025.
- Exelixis conducted the STELLAR-305 trial, investigating zanzalintinib and pembrolizumab, while Robert Burns maintained a Buy rating.
- Zacks Investment Research provided stock analysis and recommendations for Exelixis on August 30, 2025.
- Dana T. Aftab was appointed Executive Vice President, R&D at Exelixis on August 30, 2025.
- Exelixis, a company, is headquartered in Alameda, California.